NCT05887999View on ClinicalTrials.gov

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 12, 2023

Primary Completion Date

February 21, 2024

Study Completion Date

February 21, 2024

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

LY3532226

Administered subcutaneously (SC).

DRUG

Placebo

Administered SC.

Trial Locations (1)

91911

ProSciento, Inc, Chula Vista

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT05887999 - A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter